AUTH/2430/8/11: Johnson & Johnson misleading Nicorette QuickMist mailing (60-second craving relief and cost per day)

📅 2011 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2430/8/11
PartiesGlaxoSmithKline Consumer Healthcare v Johnson & Johnson Limited
ProductNicorette QuickMist (nicotine mouthspray)
MaterialPrescriber mailing (ref 06458)
Main issuesImplied claim that “60 second craving relief” applied to “breakthrough cravings”; misleading cost-per-day claim due to dosing and pack/price presentation
Key claims challenged“60 second craving relief”; “Breakthrough cravings can jeopardise a quit attempt”; “Cost of treatment: £1.23 per day for an average 20 per day smoker, using one spray in place of their normal cigarette**” (**Based on the NHS cost of the duo pack)
Panel findingsMisleading by juxtaposition/terminology ambiguity; cost claim misleading (two-spray study not made clear; single pack image vs duo pack cost basis; footnote insufficient)
Breach clausesClause 7.2 (x2)
SanctionsUndertaking received; Additional sanctions: Not stated
Complaint received08 August 2011
Case completed15 September 2011
AppealNo appeal
Applicable Code year2011

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • GlaxoSmithKline Consumer Healthcare complained about a prescriber mailing (ref 06458) for Nicorette QuickMist (nicotine mouthspray) distributed by Johnson & Johnson Limited.
  • The mailing prominently claimed “60 second craving relief” (referenced to “Data on file 002”) and included a bullet “Breakthrough cravings can jeopardise a quit attempt”.
  • The supporting study for the “60 second” claim used two sprays per cigarette replacement, but the mailing did not make the two-spray regimen clear.
  • The mailing also claimed: “Cost of treatment: £1.23 per day for an average 20 per day smoker, using one spray in place of their normal cigarette**” with a footnote “**Based on the NHS cost of the duo pack”.
  • The visual on the mailing showed a single dispenser pack (NHS cost £11.48), while the cost calculation was based on the duo pack (NHS cost £18.50; £9.25 per dispenser).
⚖️

Outcome

  • The Panel ruled the juxtaposition of “60 second craving relief” with “Breakthrough cravings can jeopardise a quit attempt” was misleading. Breach of Clause 7.2.
  • The Panel ruled the “£1.23 per day” cost claim was misleading given the undisclosed two-spray regimen underpinning the key efficacy claim and the pack image/price mismatch. Breach of Clause 7.2.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training